Skip to main content
Visiomed Group SA logo

Visiomed Group SA — Investor Relations & Filings

Ticker · ALVMG ISIN · FR0013481835 LEI · 969500ZH8PE9A98GLY06 PA Human health and social work activities
Open in API
Filings indexed 337 across all filing types
Latest filing 2023-08-23 Legal Proceedings Report
Country FR France
Listing PA ALVMG

About Visiomed Group SA

https://www.kleaholding.com/

Klea Holding, formerly known as Visiomed Group SA, is an international holding company focused on the acquisition, development, and digitalization of businesses across multiple sectors. The company originated as an innovator in medical electronics, known for developing the ThermoFlash non-contact infrared thermometer. It has since transitioned its strategy to a holding structure, leveraging financial management to foster growth and value creation in its portfolio companies. While its investment scope is broad, Klea Holding maintains a significant presence in the innovative healthcare sector through subsidiaries that operate digitalized medical diagnostic centers and provide connected health and teleconsultation solutions.

Recent filings

Filing Released Lang Actions
Visiomed Group dismantles the defamatory and false allegations made against the company, reveals the motives of the persons behind them and launches a legal counterattack
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled and formatted as a "Press release" dated August 21, 2023. It details the company's response to defamatory allegations from another entity (BewellConnect), discusses the impact on the share price, and announces immediate legal counter-actions, including alerting the Autorité des Marchés Financiers (AMF) and filing a complaint for defamation. This type of immediate, reactive communication regarding market-sensitive events, legal disputes, and share price impact, issued via a press release format, is typically classified as a general regulatory announcement or a specific legal/market event disclosure. Since the content is primarily a rebuttal to allegations and an announcement of legal steps, it fits best under the general regulatory announcement category, as it is not a formal financial report (10-K, IR, ER) or a specific legal filing document itself, but rather a public statement about legal/market events. Given the options, 'Regulatory Filings' (RNS) serves as the best fallback for significant, non-standard public disclosures that impact the market, especially when it involves alerting regulators (AMF) and announcing legal action, which is often disseminated via RNS in European markets. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal proceeding report (LTR), but rather a response to one.
2023-08-23 English
Visiomed Group démonte les allégations diffamatoires et mensongères dont elle est la victime, révèle les motivations de ses auteurs et lance une contre-attaque judiciaire
Legal Proceedings Report Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and details Visiomed Group's response to defamatory allegations from another entity (BewellConnect). It discusses legal actions being taken (filing complaints, alerting the AMF), refutes specific financial claims, and provides updates on the company's operational performance and strategy (growth figures, expansion plans). This type of document, which is a formal, immediate public statement addressing market-sensitive issues (like legal disputes impacting stock price) but is not a full statutory report (like 10-K or IR), typically falls under general regulatory announcements or press releases concerning corporate events. Since it is a detailed response to a specific corporate conflict and legal threat, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR). Given the primary focus is on refuting claims and announcing counter-legal action, LTR is plausible, but RNS serves as the best catch-all for significant, non-standard press releases concerning market integrity and legal disputes that aren't covered by other specific codes (like DIV, CAP, etc.). The document is substantial (over 12k characters) and contains substantive information, not just an announcement of a report, thus ruling out RPA. I will classify it as RNS as it is a broad regulatory announcement concerning market integrity and legal matters.
2023-08-21 French
Visiomed Group : démenti formel à la suite d'un communiqué mensonger et diffamatoire
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Communiqué de presse") from Visiomed Group dated August 18, 2023. It addresses a false and defamatory press release from another entity (BewellConnect) and announces the suspension of trading to allow for a proper response. Crucially, it reassures shareholders about the company's financial health, citing the upcoming publication of H1 2023 revenue and promising a more substantial communication on Monday, August 21st. Since this document is a short, immediate reaction to an external event (defamation/trading halt) and serves to manage investor relations and announce future communication, it does not fit the definition of a comprehensive report (10-K, IR) or a specific financial announcement (ER, DIV). It is a general, urgent corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-standard regulatory/corporate communication that doesn't fit the highly specific categories like DIRS, MANG, or LTR, although it has elements of reputation management. However, since it is a direct response to a crisis and a statement of fact/denial, it is a general corporate announcement. RNS is the best fit as a general regulatory/corporate announcement fallback.
2023-08-18 French
Information relative au nombre total de droits de vote et au nombre d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et au nombre d'actions composant le capital social" (Information relative to the total number of voting rights and the number of shares comprising the share capital). It explicitly states it is publishing this information in accordance with Article 223-16 of the AMF General Regulation (French financial market authority). The core content is a table detailing the number of shares and voting rights as of August 1, 2023. This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing. While it is a formal announcement, it doesn't fit perfectly into the standard US SEC forms (like 10-K, ER, etc.). Among the provided definitions, it most closely relates to changes in share structure or mandatory disclosures. Since it details the total number of shares and voting rights, it is a fundamental capital structure update. The closest fit among the provided codes is 'SHA' (Share Issue/Capital Change) or potentially 'RNS' (Regulatory Filings) if SHA is too specific. Given the content is a direct report on the capital structure (number of shares and voting rights), SHA is the most appropriate classification, as it directly concerns the share capital base. The document length is short (3383 chars), but it is the primary disclosure, not an announcement of another report.
2023-08-01 French
Visiomed Group continues its hyper-growth trajectory with revenue up 41% in the 1er half of 2023
Earnings Release Classification · 98% confidence The document is titled "Press release" and presents unaudited revenue figures for H1 2023, highlighting key performance indicators and future expectations. It explicitly states that the full H1 2023 results will be available on October 9, 2023. This structure—a brief announcement summarizing key financial highlights for a period (H1 2023) before the comprehensive report is released—is characteristic of an Earnings Release (ER). It is not the full comprehensive report (IR) nor is it a mere announcement of a report's publication (RPA), as it contains substantive financial data and commentary. H1 2023
2023-08-01 English
Visiomed Group poursuit sa trajectoire d''hyper croissance avec un chiffre d''affaires en progression de 41% au 1er semestre 2023
Earnings Release Classification · 99% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and presents the "chiffre d'affaires non audité du premier semestre 2023" (unaudited revenue for the first half of 2023). It provides key financial highlights (revenue figures, growth percentages, patient volumes) for a specific period (H1 2023) but is not the comprehensive, detailed report itself (like a 10-K or a full IR). The text also mentions when the full results will be available ("Résultats du 1er semestre 2023 : les résultats du premier semestre 2023 seront disponibles le lundi 9 octobre 2023"). This structure—a brief announcement of preliminary/key results for a period—is characteristic of an Earnings Release (ER). It is too detailed for a simple Report Publication Announcement (RPA) but lacks the depth of a full Interim Report (IR). H1 2023
2023-07-31 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.